earnings
confidence high
sentiment positive
materiality 0.80
Nkarta Q2 net loss $27M; NKX101 AML 60% CR, NKX019 NHL 50% CR
Nkarta, Inc.
2022-Q2 EPS reported
-$1.38
- Q2 2022 net loss $27.0M ($0.61/share); cash & investments $415.0M, sufficient into 2025.
- NKX101 Phase 1: 3/5 AML patients at higher dose achieved CR (60%); 2 of 3 MRD-negative.
- NKX019 Phase 1: 3/6 NHL patients at higher dose achieved CR (50%); included DLBCL and MCL.
- Raised ~$215.6M net from public offering in April 2022; lease amendments add $15M tenant improvements.
- Promoted leaders: Dr. Brandenberger to CTO, Yvonne Li to CAO, Dr. Shook to VP Clinical Dev.